Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study
Journal of Investigative Dermatology2007Vol. 128(1), pp. 35–44
Citations Over TimeTop 1% of 2007 papers
Maja Mockenhaupt, Cécile Viboud, Ariane Dunant, Luigi Naldi, Sima Halevy, Jan Nico Bouwes Bavinck, Alexis Sidoroff, Jürgen Schneck, Jean‐Claude Roujeau, Antoine Flahault
Related Papers
- → Toxic epidermal necrolysis: a paradigm of critical illness(2017)34 cited
- → Stevens-Johnson syndrome and toxic epidermal necrolysis(2017)19 cited
- → Pattern and impact of drug-induced liver injury in South African patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and a high burden of HIV(2021)4 cited
- → A Case Study of Toxic Epidermal Necrolysis(2019)1 cited
- → Predicting sepsis in Stevens-Johnson syndrome–toxic epidermal necrolysis: Should dermatologists be pro-procalcitonin?(2019)